학술논문
X-linked hypophosphataemic rickets in children: clinical phenotype, therapeutic strategies, and molecular background.
Document Type
Academic Journal
Author
Obara-Moszynska M; Department of Paediatric Endocrinology and Rheumatology, Poznan University of Medical Sciences, Institute of Paediatrics, Poznan, Poland.; Rojek A; Department of Paediatric Endocrinology and Rheumatology, Poznan University of Medical Sciences, Institute of Paediatrics, Poznan, Poland. aleksandra.rojek@gmail.com.; Kolesinska Z; Department of Paediatric Endocrinology and Rheumatology, Poznan University of Medical Sciences, Institute of Paediatrics, Poznan, Poland.; Jurkiewicz D; Department of Medical Genetics, The Children's Memorial Health Institute, Warsaw, Poland.; Chrzanowska KH; Department of Medical Genetics, The Children's Memorial Health Institute, Warsaw, Poland.; Niedziela M; Department of Paediatric Endocrinology and Rheumatology, Poznan University of Medical Sciences, Institute of Paediatrics, Poznan, Poland.
Source
Publisher: Via Medica Country of Publication: Poland NLM ID: 0370674 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2299-8306 (Electronic) Linking ISSN: 0423104X NLM ISO Abbreviation: Endokrynol Pol Subsets: MEDLINE
Subject
Language
English
Abstract
Introduction: X-linked hypophosphataemic rickets (XLHR) is the most common form of hypophosphataemic rickets (HR), which is caused by mutations in the PHEX gene. The aim of this work was to investigate the clinical phenotype, therapeutic strategies, and molecular background of HR in children hospitalised in our clinic.
Material and Methods: Eleven patients aged 5.7-18.25 years were included in this study. Molecular analysis was performed using polymerase chain reaction (PCR) and direct sequencing. The PHEX gene was examined in all of the patients, whereas the FGF23 gene was analysed in 5 patients. All of them were treated with alphacalcidol and phosphorus, and 3 were additionally treated with recombinant human growth hormone (rhGH).
Results: The mean age at HR diagnosis was 4.05 ± 3.35 years. The mean htSDS was -2.99 ± 1.19. In 2 of the 3 patients treated with rhGH the height gain was +0.4SD and +0.3SD, respectively. In 10 of 11 patients, PHEX gene mutations were found. In 2 children, novel mutations in the PHEX gene were identified: c.325_326dupCA, N110Ifs*7 in one patient and c.899_900delTG, M300Kfs*4 in the remaining one, which coexisted with a known polymorphism c.1769-10C > T, rs3752433. In one patient, a novel deletion of exon 14 and 2 polymorphisms were detected: c.1646-46T > C, g.180417T > C, rs3213493 in intron 15 (known) and g.189156C > T in intron 17 (novel).
Conclusion: We report 3 novel mutations in the PHEX responsible for HR. Additionally, this study reports the effects of rhGH therapy for growth promotion in HR.
Material and Methods: Eleven patients aged 5.7-18.25 years were included in this study. Molecular analysis was performed using polymerase chain reaction (PCR) and direct sequencing. The PHEX gene was examined in all of the patients, whereas the FGF23 gene was analysed in 5 patients. All of them were treated with alphacalcidol and phosphorus, and 3 were additionally treated with recombinant human growth hormone (rhGH).
Results: The mean age at HR diagnosis was 4.05 ± 3.35 years. The mean htSDS was -2.99 ± 1.19. In 2 of the 3 patients treated with rhGH the height gain was +0.4SD and +0.3SD, respectively. In 10 of 11 patients, PHEX gene mutations were found. In 2 children, novel mutations in the PHEX gene were identified: c.325_326dupCA, N110Ifs*7 in one patient and c.899_900delTG, M300Kfs*4 in the remaining one, which coexisted with a known polymorphism c.1769-10C > T, rs3752433. In one patient, a novel deletion of exon 14 and 2 polymorphisms were detected: c.1646-46T > C, g.180417T > C, rs3213493 in intron 15 (known) and g.189156C > T in intron 17 (novel).
Conclusion: We report 3 novel mutations in the PHEX responsible for HR. Additionally, this study reports the effects of rhGH therapy for growth promotion in HR.